Resilient Biotics

Resilient Biotics is developing non-antibiotic, microbiome-based therapeutics to combat complex respiratory infections with applications in human and animal health. The company utilizes a proprietary discovery platform that incorporates high resolution genomic analyses, in-house machine learning algorithms, and targeted in vitro assays to identify naturally occurring microbiome-derived strains that have immune activation and pathogen inhibition properties in respiratory tissues. Resilient Biotics has a broad pipeline of actives addressing both viral and bacterial infectious diseases including positive in vivo efficacy data across multiple species

Microbiome and respiratory health

Resilient biotics operates in the Biotechnology research industry.

Resilient biotics's revenue is 11m - 100m

Resilient biotics has 11 - 50 employees.